An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice

Nutrition and Cancer

Volumn 67, Issue 6, 2015, Pages 912-920

  Nakamura, Kentaro ^a   Sasayama, Akina ^a   Takahashi, Takeshi ^a   Yamaji, Taketo ^a  

^a MEIJI DAIRIES CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FLUOROURACIL; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CALORIC INTAKE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIET THERAPY; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; IMMUNE MODULATING DIET; INTERMETHOD COMPARISON; LOW DRUG DOSE; MOUSE; MUSCLE MASS; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; SKELETAL MUSCLE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COLON; COLONIC NEOPLASMS; DIET; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CACHEXIA; CELL LINE, TUMOR; COLON; COLONIC NEOPLASMS; DIET; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENERGY INTAKE; FLUOROURACIL; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; ORGAN SIZE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939617291     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.1053495     Document Type: Article

References (48)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489-495, 2011.
2. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, et al.: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9, 629-635, 2008.
3. Isenring EA, Capra S, and Bauer JD: Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 91, 447-452, 2004.
4. Ravasco P, Monteiro-Grillo I, Marques Vidal P, and Camilo ME: Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head & Neck 27, 659-668, 2005.
5. Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, et al.: ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 25, 245-259, 2006.
6. Tisdale MJ: Mechanisms of Cancer Cachexia. Physiol Rev 89, 381-410, 2009.
7. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8, 265-269, 2005.
8. Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, et al.: Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head & Neck 29, 244-248, 2007.
9. Martín F, Santolaria F, Batista N, Milena A, González-Reimers E, et al.: Cytokine levels (IL-6 and IFN-g), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80-86, 1999.
10. Ravasco P, Monteiro-Grillo I, and Camilo M: How Relevant Are Cytokines in Colorectal Cancer Wasting? Cancer J 13, 392-398, 2007.
11. Fearon K: Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44, 1124-1132, 2008.
12. Baldwin C: Nutritional support for malnourished patients with cancer. Curr Opin Support Palliat Care 5, 29-36., 2011.
13. Pontes-Arruda A, DeMichele S, Seth A, and Singer P: The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J Parenter Enteral Nutr 32, 596-605, 2008.
14. Kume H, Okazaki K, Yamaji T, and Sasaki H: A newly designed enteral formula containing whey peptides and fermented milk product protects mice against concanavalin A-induced hepatitis by suppressing overproduction of inflammatory cytokines. Clin Nutr 31, 283-289, 2012.
15. Nakamura K, Ogawa S, Dairiki K, Fukatsu K, Sasaki H, et al.: A new immune-modulating diet enriched with whey-hydrolyzed peptide, fermented milk, and isomaltulose attenuates gut ischemia-reperfusion injury in mice. Clin Nutr 30, 513-516, 2011.
16. Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, et al.: Impact of enteral nutrition using a new immuno-modulating diet after liver transplantation. Hepatogastroenterology 57, 1522-1525, 2010.
17. Kaido T, Ogura Y, Ogawa K, Hata K, Yoshizawa A, et al.: Effects of post-transplant enteral nutrition with an immunomodulating diet containing hydrolyzed whey peptide after liver transplantation. World J Surg 36, 1666-1671, 2012.
18. Ishikawa D, Shimada M, Utsunomiya T, Imura S, Morine Y, et al.: Whey protein isolate, MEIN (R), can reduce liver damage early after living donor liver transplantation. Transplant International 24, 311, 2011.
19. Dong J, Yang J, Chen M, Wang X, Wu Z, et al.: A comparative study of gene vaccines encoding different extracellular domains of the vascular endothelial growth factor receptor 2 in the mouse model of colon adenocarcinoma CT-26. Cancer Biol Ther 7, 502-509, 2008.
20. Strassmann G, Fong M, Kenney J, and Jacob C: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89, 1681-1684, 1992.
21. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50, 2290-229, 1990.
22. Beaulieu J, Dupont C, and Lemieux P: Whey proteins and peptides: beneficial effects on immune health. Therapy 3, 69-78, 2006.
23. Nakamura K and Yamaji T: Immune-modulating effects of whey proteins and peptides. In: Whey: Types; Composition and Health Implications, Benitez RM and Ortero GM (eds.). New York, NY: Nova, 2012, pp. 137-152.
24. Yamaji T and Kume H: Hepatoprotective effects of whey protein and whey peptides on hepatitis. Milk Sci 56, 115-118, 2008.
25. Oz H, Chen T, and Neuman M: Nutrition intervention: a strategy against systemic inflammatory syndrome. JPEN J Parenter Enteral Nutr 33, 380-389, 2009.
26. Colomer R, Moreno-Nogueira J, García-Luna P, García-Peris P, Garcíade-Lorenzo A, et al.: N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97, 823-831, 2007.
27. Argilés J, Busquets S, and López-Soriano F: Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 668(Suppl. 1), S81-S86, 2011.
28. Fearon KCH, von Meyenfeldt MF, Moses AGW, van Geenen R, Roy A, et al.: Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut 52, 1479-1486, 2003.
29. Heyland D, Dhaliwal R, Suchner U, and Berger M: Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med 31, 327-337, 2005.
30. Nukatsuka M, Fujioka A, Saito H, Uchida J, Takeda S, et al.: Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model. Jpn J Cancer Chemother 23, 887-892, 1996.
31. Tanaka Y, Tanaka T, and Ishitsuka H: Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res 49, 5935-5939, 1989.
32. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, et al.: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5, 1001-1005, 1999.
33. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, et al.: Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr 137, 205S-210S, 2007.
34. Ranger GS, Thomas V, Jewell A, and Mokbel K.: Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 24, 2349-2351, 2004.
35. Trappe TA, Carroll CC, Dickinson JM, LeMoine JK, Haus JM, et al.: Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol 300, R655-R662, 2011.
36. Trappe TA, Standley RA, Jemiolo B, Carroll CC, and Trappe SW.: Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol 304, R198-R205, 2013.
37. Lorite MJ, Cariuk P, and Tisdale MJ.: Induction of muscle protein degradation by a tumour factor. Br J Cancer 76, 1035-1040, 1997.
38. Smith KL and Tisdale MJ.: Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 68, 314-318, 1993.
39. Lai V, George J, Richey L, Kim HJ, Cannon T, et al.: Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head & Neck 30, 67-74, 2008.
40. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS.: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79, 495-500, 1999.
41. Carson JA and Baltgalvis KA: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38, 168-176, 2010.
42. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, et al.: The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 8, 85, 2010.
43. Watanabe T, Shibata M, Nishiyama H, Soeda S, Furukawa S, et al.: Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncol Lett 7, 373-377, 2014.
44. Glass DJ: Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 13, 225-229, 2010.
45. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, et al.: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 76, 606-613, 1997.
46. Wyke S, Russell S, and Tisdale M: Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91, 1742-1750, 2004.
47. Eley H, Russell S, and Tisdale M: Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 407, 113-120, 2007.
48. Ravasco P, Monteiro-Grillo I, Vidal P, and Camilo M: Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 12, 246-252, 2004.